Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06293742 · ClinicalTrials.gov registry record · Phase 1
ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants
A Phase 1 study, sponsored by Eccogene.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT06293742 is a Phase 1 study that has completed, run by Eccogene. The registered enrollment target is 48 participants.
The verdict
NCT06293742, a Phase 1 study, has completed, sponsored by Eccogene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, non-randomized, fixed sequence study designed to evaluate the effect of ECC5004 on single dose pharmacokinetics of Atorvastatin, Rosuvastatin, Digoxin and Midazolam in healthy participants.
Interventions
- DRUG Midazolam
- DRUG Rosuvastatin
- DRUG Digoxin
- DRUG Atorvastatin
- DRUG ECC5004
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2024-02-08 |
| Est. Completion | 2024-04-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06293742
The ClinicalTrials.gov registry entry for NCT06293742 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eccogene, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Midazolam is the first listed.
NCT06293742 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06293742 about?
NCT06293742 is a clinical study titled "ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants". This is a Phase 1, open-label, non-randomized, fixed sequence study designed to evaluate the effect of ECC5004 on single dose pharmacokinetics of Atorvastatin, Rosuvastatin, Digoxin and Midazolam in healthy participants.
What is the current status of trial NCT06293742?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2024-02-08. Estimated completion is 2024-04-15.
What interventions are being tested in trial NCT06293742?
The interventions under investigation include: Midazolam (DRUG), Rosuvastatin (DRUG), Digoxin (DRUG), Atorvastatin (DRUG), ECC5004 (DRUG).
Who is sponsoring clinical trial NCT06293742?
This trial is sponsored by Eccogene, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.